Summary of findings: low‐dose vs high‐dose PERT
- Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 17 participantsVery low
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of Findings Table ‐ Low changes death or BPD at 36 weeks PMA compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of Findings Table ‐ Low changes BPD, defined as supplemental oxygen or positive pressure support use… compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
It is very uncertain whether summary of Findings Table ‐ Low changes treatment failure or need for mechanical ventilation compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
It is very uncertain whether summary of Findings Table ‐ Low changes mortality, by hospital discharge compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of Findings Table ‐ Low changes BPD, defined as supplemental oxygen or positive pressure support use… compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
It is very uncertain whether summary of Findings Table ‐ Low changes death or BPD at 36 weeks' PMA compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
Low‐dose mifepristone (< 25 mg) leads to lower observed number of pregnancies (all women) compared with levonorgestrel 1.5 mg (high certainty).
Low‐dose mifepristone (< 25 mg) may leads to lower any side effect compared with levonorgestrel 1.5 mg (low certainty).
Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ nausea compared with levonorgestrel 1.5 mg (moderate certainty).
Low‐dose mifepristone (< 25 mg) showed no clear difference in specific side effect ‐ vomiting compared with levonorgestrel 1.5 mg (low certainty).
Low‐dose mifepristone (< 25 mg) leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (high certainty).
Low‐dose mifepristone (< 25 mg) may leads to lower menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).